AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study

AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (HCC), according to the updated results from the HIMALAYA Phase 3 trial. An unparalleled one in four patients were still alive four years after treatment with this novel combination therapy, marking the longest survival […]

SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer

SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer

In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee’s Pharmaceutical, has announced the enrollment of the first patient in China for their phase 3 trial, named PHOCUS. This trial will assess the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer and […]